Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ) is now available.
Sawai Group Holdings Co., Ltd. announced that its subsidiary, Sawai Pharmaceutical Co., Ltd., has filed a final appeal with the Supreme Court following an unfavorable ruling by the IP High Court in a patent infringement lawsuit concerning the use patent of Nalfurafine. The company is reviewing the potential financial impact of this legal development and will inform stakeholders of any significant updates.
The most recent analyst rating on (JP:4887) stock is a Sell with a Yen1650.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
More about SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd. operates in the pharmaceutical industry, primarily focusing on the production and distribution of generic drugs through its subsidiary, Sawai Pharmaceutical Co., Ltd. The company is listed on the Prime Market of the Tokyo Stock Exchange.
Average Trading Volume: 577,452
Technical Sentiment Signal: Sell
Current Market Cap: Yen174.7B
For detailed information about 4887 stock, go to TipRanks’ Stock Analysis page.